Edgewise Therapeutics (EWTX) put fresh clinical data in front of investors after presenting updated long term results from its MESA open label extension study of sevasemten in Becker muscular dystrophy.

At a share price of US$29.94, Edgewise Therapeutics has seen a 26.76% 90 day share price return and a 297.61% three year total shareholder return. This suggests momentum has built as sevasemten data and recent conference appearances keep attention on the story.

If this Becker muscular dystrophy update has you thinking about where else new therapies could emerge, our screener of 34 healthcare AI stocks is a useful way to spot other potential ideas in the space.

With shares up 26.76% over 90 days and sitting at a 34% discount to the average analyst price target, the key question is whether Edgewise is still mispriced or if the market is already factoring in future growth.

Preferred Price to Book of 6.1x, Is it justified?

Edgewise trades on a P/B of 6.1x, which is materially higher than the broader US pharmaceuticals sector but sits below the peer group average highlighted in the data.

The P/B ratio compares the company’s market value to its book value, so a higher figure often reflects investors assigning more value to future potential than to the current balance sheet. For a pre revenue, loss making biotech like Edgewise, that usually means the market is focusing heavily on the development pipeline rather than present financials.

Here, the company screens as expensive versus the wider US pharmaceuticals industry average P/B of 2.1x. This signals that investors are paying a premium relative to many sector names. At the same time, the 6.1x multiple is described as good value against a much higher peer average of 21.7x. This highlights how concentrated expectations can be for companies clustered around similar early stage drug development profiles.

Result: Price to book of 6.1x (ABOUT RIGHT)

However, you still need to weigh clinical and regulatory risk around sevasemten, as well as the ongoing net loss of US$167.795 million, against that premium valuation.

Next Steps

If this all sounds mixed, now is the time to look through the numbers yourself and decide how you feel about the risk profile. You can start by reviewing the 3 important warning signs that our work has highlighted for this company.

Ready to size up your next idea?

If you stop with a single stock, you risk missing other opportunities that may fit your style even better, so widen your search before you commit.

• Spot potential bargains quickly by scanning our list of 47 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their qualities.
• Prioritise resilience by checking out 68 resilient stocks with low risk scores, focused on companies that score well on stability and overall risk profile.
• Get ahead of the crowd by reviewing a screener containing 25 high quality undiscovered gems that screens for quality businesses the market may not be paying close attention to yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.